Professor Dale Gerding, a world leader in C. difficile infections and a member of the Destiny Pharma Scientific Advisory Board recently spoke to Equity Development about the significant problem of CDI and how Destiny Pharma’s novel NTCD-M3 clinical programme can provide a breakthrough in patients’ treatment. The interview can be viewed here
Destiny Pharma is pleased to be highlighted in an analyst note from WH Ireland titled, “WHI Sector Comment: Strategic themes in healthcare: an AIM perspective“.
A copy of the report can be found here
Destiny Pharma is presenting at Emerging Antimicrobials and Diagnostics in AMR 2021 on 18 November 2021.
If you would like to meet virtually with Destiny Pharma, please email us on email@example.com
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Destiny Pharma’s SAB Member Professor Dale Gerding is Keynote Speaker at C. diff. International Conference
Brighton, United Kingdom – 4th November 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that its Scientific Advisory Board Member, Professor Dale Gerding, MD, MACP, FIDSA, FSHEA, will be giving a keynote presentation at the C. diff International Conference & Health EXPO to be held in-person and virtually from 4th – 5th November 2021. Destiny Pharma is a Gold Sponsor of the event.
Prof. Gerding’s presentation titled ‘Adjunctive Therapy for CDI to Prevent Recurrence: What Works and Practical Issues’ will be at 7.20pm – 7.40pm GMT/ 2.20pm – 2.40pm EST on Friday 5th November 2021. Registration for the Conference can be found here.
Destiny Pharma’s late-stage asset, NTCD-M3, is a novel microbiome therapeutic being developed to reduce the recurrence of C. difficile infections (CDI) in the gut. CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.
Neil Clark, Chief Executive Officer of Destiny Pharma, said: “We are delighted to be sponsoring this important global event which raises C.difficile awareness and brings together patients and drug developers. We are also very proud to have our Scientific Advisory Member, Professor Dale Gerding invited as a Keynote Speaker. Prof. Gerding is a world-leading expert in C. difficile infections and the discoverer of NTCD-M3, Destiny Pharma’s Phase 3 ready microbiome therapeutic. NTCD-M3 has the potential to become the leading treatment for CDI, as its strong Phase 2 clinical data and target product profile shows clear advantages to both existing CDI treatment options and those currently in clinical development.”
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communication
Hollie Vile / Manel Mateus / Vici Rabbetts
+44 (0) 208 078 4357
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
MC Services AG
Anne Hennecke / Andreas Burckhardt
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
Forward looking statements
Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks” “could” “targets” “assumes” “positioned” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable, but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.